Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy

Deanna Cettomai1, Justin C McArthur

  • 1Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Archives of Neurology
|February 11, 2009
PubMed
Abstract

Insights

Mirtazapine shows promise for treating progressive multifocal leukoencephalopathy (PML) in HIV patients. Three of four patients experienced clinical improvement, with early treatment yielding the best results.

Area of Science:

  • Neurovirology
  • Clinical Neurology
  • Pharmacology

Background:

  • Progressive multifocal leukoencephalopathy (PML) is a serious opportunistic infection in human immunodeficiency virus (HIV)-positive individuals.
  • There is a critical need for effective treatments for PML, particularly in the context of HIV infection.

Observation:

  • This study presents a case series of four HIV-positive patients diagnosed with PML.
  • The patients received mirtazapine, an antidepressant, at a dosage of 15 mg nightly as a potential therapeutic intervention.

Findings:

  • Three out of the four patients exhibited objective clinical improvement following mirtazapine treatment.
  • One patient demonstrated positive changes on cranial magnetic resonance imaging (MRI).
  • The most substantial clinical benefit was observed in the patient treated earliest after PML symptom onset.

Implications:

  • Mirtazapine may serve as a beneficial treatment or prophylactic agent for PML in individuals with HIV.
  • Further research is warranted to confirm the efficacy and optimal use of mirtazapine in managing PML.

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...